Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med. 2005;33:721-726.
Kuriyan M, Carson JL. Blood transfusion risks in the intensive care unit. Crit Care Clin. 2004;20:237-253.
1. Linden JV, Wagner K, Voytovich AE, et al. Transfusion errors in New York state: an analysis of 10 years' experience. Transfusion. 2000;40:1207-1213.
2. Spiess BD. Risks of transfusion: outcome focus. Transfusion. 2004;44(12 Suppl):4S-14S.
3. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion. 1990;30:583-590.
4. Serious Hazards of Transfusion. SHOT report 2008. http://www.shotuk.org (last accessed 8 August 2017).
5. Yazer MH, Podlosky L, Clarke G, et al. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion. 2004;44:10-15.
6. Paglino JC, Pomper GJ, Fisch GS, et al. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion. 2004;44:16-24.
7. King KE, Shirey RS, Thoman SK, et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion. 2004;44:25-29.
8. Tobian AA, King KE, Ness PM. Transfusion premedications: a growing practice not based on evidence. Transfusion. 2007;47:1089-1096.
9. Domen RE, Hoeltge GA. Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med. 2003;127:316-320.
10. Stainsby D, Jones H, Asher D, et al. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev. 2006;20:273-282.
11. Vamvakas EC, Pineda AA, Reisner R, et al. The differentiation of delayed hemolytic and delayed serologic transfusion reactions: incidence and predictors of hemolysis. Transfusion. 1995;35:26-32.
12. Mazzei CA, Popovsky MA, Kopko PM. Noninfectious complications of blood transfusion. In: Roback JD, Combs MR, Grossman BJ, et al., eds. Technical Manual, 16th Ed. Bethesda, MD: American Association of Blood Banks; 2008:715-749.
13. Finlay HE, Cassorla L, Feiner J, et al. Designing and testing a computer-based screening system for transfusion-related acute lung injury. Am J Clin Pathol. 2005;124:601-609.
14. Rana R, Fernandez-Perez ER, Khan SA, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion. 2006;46:1478-1483.
15. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;105:2266-2273.
16. Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: a review. Chest. 2004;126:249-258.
17. Heddle NM. Pathophysiology of febrile nonhemolytic transfusion reactions. Curr Opin Hematol. 1999;6:420-426.
18. Middelburg RA, van Stein D, Briët E, et al. The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion. 2008;48:2167-2176.
19. Dwyre DM, Holland PV. Transfusion-associated graft-versus-host disease. Vox Sang. 2008;95:85-93.
20. Yomtovian RA, Palavecino EL, Dykstra AH, et al. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion. 2006;46:719-730.
21. Leiby DA, Kerr KL, Campos JM, et al. A retrospective analysis of microbial contaminants in outdated random-donor platelets from multiple sites. Transfusion. 1997;37:259-263.
22. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med. 2005;33:721-726.
23. Huerta-Alardin AL, Varon J, Marik PE. Bench-to-bedside review: rhabdomyolysis--an overview for clinicians. Crit Care. 2005;9:158-169.
24. Lieberman P, Kemp SF, Oppenheimer J, et al. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005;115(3 Suppl 2):S483-S523.
25. Lin RY, Curry A, Pesola GR, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med. 2000;36:462-468.
26. Mueller-Eckhardt C, Kiefel V. High-dose IgG for post-transfusion purpura--revisited. Blut. 1988;57:163-167.
27. Anderson D, Ali K, Blanchette V, et al. Guideline on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007;21(suppl 1):S9-S56.
28. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy. 2000;30:1144-1150.
29. Kuriyan M, Carson JL. Blood transfusion risks in the intensive care unit. Crit Care Clin. 2004;20:237-253.
30. Perrota PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Rev. 2001;15:69-83.
31. Geiger TL, Howard SC. Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice? Transfus Med Rev. 2007;21:1-12.
32. Blajchman MA. The clinical benefits of the leukoreduction of blood products. J Trauma. 2006;60(6 Suppl):S83-S90.
33. Martí-Carvajal AJ, Solà I, González LE, et al. Pharmacological interventions for the prevention of allergic and febrile non-haemolytic transfusion reactions. Cochrane Database Syst Rev. 2010 Jun 16;6:CD007539.
34. Australian & New Zealand Society of Blood Transfusion. Guidelines for prevention of transfusion-associated graft-versus-host disease (TA-GVHD). Sydney, Australia: Australian & New Zealand Society of Blood Transfusion Ltd; 2011.
35. Middelburg RA, van Stein D, Zupanska B, et al. Female donors and transfusion-related acute lung injury. Transfusion. 2010;50:2447-2454.
36. Schmickl CN, Mastrobuoni S, Filippidis FT, et al. Male-predominant plasma transfusion strategy for preventing transfusion-related acute lung injury: a systematic review. Crit Care Med. 2015;43:205-225.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台